Profitability
This table compares Biocorrx and Bioqual’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Biocorrx | N/A | N/A | -90.89% |
| Bioqual | -2.27% | -2.69% | -1.50% |
Volatility and Risk
Biocorrx has a beta of 0.19, indicating that its share price is 81% less volatile than the S&P 500. Comparatively, Bioqual has a beta of -0.2, indicating that its share price is 120% less volatile than the S&P 500.
Valuation & Earnings
This table compares Biocorrx and Bioqual”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Biocorrx | $800,000.00 | 7.90 | -$3.44 million | ($0.12) | -1.75 |
| Bioqual | $48.87 million | 0.60 | -$1.05 million | ($1.08) | -30.56 |
Bioqual has higher revenue and earnings than Biocorrx. Bioqual is trading at a lower price-to-earnings ratio than Biocorrx, indicating that it is currently the more affordable of the two stocks.
Summary
Biocorrx beats Bioqual on 6 of the 9 factors compared between the two stocks.
About Biocorrx
BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant; and distributes UnCraveRx weight loss management program, a medically assisted weight management program to reduce food cravings combined with on-demand virtual lifestyle support, fitness, and nutrition. The company is also developing BICX101, an injectable naltrexone product; and BICX104, an implantable naltrexone implant for the treatment of opioid addiction and alcoholism. It distributes its program to healthcare providers, independent licensed clinics, and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is based in Anaheim, California.
About Bioqual
Bioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States. The company provides research services in the areas of COVID-19, AIDS, influenza, RSV infection, and flavivirus infections, including zika, dengue, malaria, hepatitis, and cancer. Its services also include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation, and other cell-based assays. In addition, the company provides animal research model related services. Bioqual, Inc. was founded in 1981 and is based in Rockville, Maryland.
Receive News & Ratings for Biocorrx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocorrx and related companies with MarketBeat.com's FREE daily email newsletter.
